Literature DB >> 2441731

Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

P Kuusela, C Haglund, P J Roberts, H Jalanko.   

Abstract

Serum levels were determined in 434 patients with benign and malignant gastrointestinal diseases and compared with the serum concentrations of carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP). The highest proportion of elevated CA-50 levels (greater than 17 U ml-1) was found in patients with pancreatic cancer (73%). High levels were mainly associated with advanced cancer, but also half of the patients with a resectable pancreatic tumour had an increased CA-50 concentration. The CA-50 level was elevated in 37-58% of patients with colorectal, gastric, hepatocellular and biliary tract cancers. In all gastrointestinal cancers, CA-50 gave additional information compared with CEA and AFP, except in hepatocellular carcinoma where AFP was the best marker.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2441731      PMCID： PMC2002047          DOI： 10.1038/bjc.1987.137

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Carcinoembryonic antigen in malignant and nonmalignant gynecologic tumors: circulating levels and tissue localization.

Authors:  E M Rutanen; J Lindgren; P Sipponen; U P Stenman; E Saksela; M Seppäla
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

2.  Immunologic diagnosis and prognosis of human digestive-tract cancer: carcinoembryonic antigens.

Authors:  N Zamcheck; T L Moore; P Dhar; H Kupchik
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

Review 3.  alpha-Fetoprotein in cancer and fetal development.

Authors:  E Ruoslahti; M Seppälä
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

4.  Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for -fetoprotein. Demonstration of -fetoprotein in serum of healthy human adults.

Authors:  E Ruoslahti; M Seppälä
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

5.  Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody.

Authors:  O Nilsson; J E Månsson; L Lindholm; J Holmgren; L Svennerholm
Journal:  FEBS Lett       Date:  1985-03-25       Impact factor: 4.124

6.  Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma.

Authors:  J Holmgren; L Lindholm; B Persson; T Lagergård; O Nilsson; L Svennerholm; C M Rudenstam; B Unsgaard; F Yngvason; S Pettersson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-19

7.  Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma.

Authors:  J E Månsson; P Fredman; O Nilsson; L Lindholm; J Holmgren; L Svennerholm
Journal:  Biochim Biophys Acta       Date:  1985-03-27

8.  Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.

Authors:  C Haglund; P Kuusela; H Jalanko; P J Roberts
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

9.  Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Authors:  H Jalanko; P Kuusela; P Roberts; P Sipponen; C A Haglund; O Mäkelä
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

10.  A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms.

Authors:  M J Cooper; C R Mackie; D B Skinner; A R Moossa
Journal:  Br J Surg       Date:  1979-02       Impact factor: 6.939
View more
  5 in total

1.  Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.

Authors:  E Heyderman; S E Larkin; P J O'Donnell; A M Haines; P J Warren; A Northeast; A G Grant
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

2.  Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Authors:  P Kuusela; C Haglund; P J Roberts
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

3.  Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.

Authors:  C Haglund; J Lindgren; P J Roberts; S Nordling
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

4.  Preoperative serum levels of CEA and CA 242 in colorectal cancer.

Authors:  M Carpelan-Holmström; C Haglund; P Kuusela; H Järvinen; P J Roberts
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

5.  Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

Authors:  C Haglund; J Lindgren; P J Roberts; P Kuusela; S Nordling
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.